Last reviewed · How we verify

NCT07329543

AGE Burden and Response to Antiresorptive Therapy in Osteoporosis

Not yet recruiting Last updated 9 January 2026
What this trial tests

trial in Osteoporosis in 240 participants. Not yet recruiting.

Timeline
15 January 2026
Primary endpoint
15 January 2027
15 April 2027

Quick facts

Lead sponsorBursa City Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment240
Start date15 January 2026
Primary completion15 January 2027
Estimated completion15 April 2027

Conditions studied

Sponsor

Bursa City Hospital

Who can join

50 and older, any sex, with Osteoporosis or Postmenopausal Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Osteoporosis is a common condition that increases the risk of bone fractures. Although antiresorptive treatments such as bisphosphonates and denosumab are effective in increasing bone mineral density, some patients continue to experience fractures despite treatment. Advanced glycation end-products (AGEs) accumulate in the body over time and can negatively affect bone quality by altering collagen structure and increasing inflammation. The role of AGE burden in predicting response to osteoporosis treatment has not been fully established. This prospective cohort study aims to evaluate whether baseline AGE burden, measured non-invasively using skin autofluorescence, is associated with treatment response in patients receiving antiresorptive therapy for osteoporosis. Changes in bone mineral density, bone turnover markers, and fracture outcomes will be analyzed in relation to baseline AGE levels. The results of this study may help identify patients at risk for reduced treatment response and residual fracture risk.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Osteoporosis

Currently open trials in the same condition.

Other Bursa City Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07329543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing